Abstract：
OBJECTIVE: To investigate the seroprevalence of the community-acquired bacterial that causes atypical pneumonia among confirmed severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) patients.
METHODS: In this cohort study, we retrospectively investigated the seroprevalence of Chlamydia pneumoniae, Mycoplasma pneumoniae, and Legionella pneumophila among randomly selected 189 confirmed COVID-19 patients at their time of hospital presentation via commercial immunoglobulin M (IgM) antibodies against these bacteria. We also carried out quantitative measurements of procalcitonin in patients\' serum.
RESULTS: The seropositivity for L. pneumophila was 12.6%, with significant distribution among patientsolder than 50 years (χ2 test, p=0.009), while those of M. pneumoniae was 6.3% and C. pneumoniae was 2.1%, indicating an overall co-infection rate of 21% among COVID-19 patients. No significant difference (χ2 test, p=0.628) in the distribution of bacterial co-infections existed between male and female patients. Procalcitonin positivity was confirmed amongst 5% of co-infected patients.
CONCLUSIONS: Our study documented the seroprevalence of community-acquired bacteria co-infection among COVID-19 patients. In this study, procalcitonin was an inconclusive biomarker for non-severe bacterial co-infections among COVID-19 patients. Consideration and proper detection of community-acquired bacterial co-infection may minimize misdiagnosis during the current pandemic and positively reflect disease management and prognosis.
METHODS: In this cohort study, we retrospectively investigated the seroprevalence of Chlamydia pneumoniae, Mycoplasma pneumoniae, and Legionella pneumophila among randomly selected 189 confirmed COVID-19 patients at their time of hospital presentation via commercial immunoglobulin M (IgM) antibodies against these bacteria. We also carried out quantitative measurements of procalcitonin in patients\' serum.
RESULTS: The seropositivity for L. pneumophila was 12.6%, with significant distribution among patientsolder than 50 years (χ2 test, p=0.009), while those of M. pneumoniae was 6.3% and C. pneumoniae was 2.1%, indicating an overall co-infection rate of 21% among COVID-19 patients. No significant difference (χ2 test, p=0.628) in the distribution of bacterial co-infections existed between male and female patients. Procalcitonin positivity was confirmed amongst 5% of co-infected patients.
CONCLUSIONS: Our study documented the seroprevalence of community-acquired bacteria co-infection among COVID-19 patients. In this study, procalcitonin was an inconclusive biomarker for non-severe bacterial co-infections among COVID-19 patients. Consideration and proper detection of community-acquired bacterial co-infection may minimize misdiagnosis during the current pandemic and positively reflect disease management and prognosis.
摘要：
目的：调查确诊的严重急性呼吸综合征冠状病毒2（SARS-COV-2）患者中引起非典型肺炎的社区获得性细菌的血清阳性率。
方法：在这项队列研究中，我们回顾性调查了肺炎衣原体的血清阳性率，肺炎支原体,随机选择的189例确诊的COVID-19患者在住院时通过针对这些细菌的商业免疫球蛋白M（IgM）抗体进行检查。我们还对患者血清中的降钙素原进行了定量测量。
结果：嗜肺菌的血清阳性率为12.6%，在50岁以上的患者焊料中具有显著分布(χ2检验，p=0.009),而肺炎支原体为6.3%，肺炎衣原体为2.1%，表明COVID-19患者的总合并感染率为21%。无显著性差异(χ2检验，p=0.628）在男性和女性患者之间存在细菌共感染的分布。在5％的共感染患者中确认了降钙素原阳性。
结论：我们的研究记录了COVID-19患者中社区获得性细菌共感染的血清阳性率。在这项研究中,降钙素原是COVID-19患者非严重细菌共感染的不确定性生物标志物。考虑和适当检测社区获得性细菌共感染可以最大程度地减少当前大流行期间的误诊，并积极反映疾病管理和预后。
方法：在这项队列研究中，我们回顾性调查了肺炎衣原体的血清阳性率，肺炎支原体,随机选择的189例确诊的COVID-19患者在住院时通过针对这些细菌的商业免疫球蛋白M（IgM）抗体进行检查。我们还对患者血清中的降钙素原进行了定量测量。
结果：嗜肺菌的血清阳性率为12.6%，在50岁以上的患者焊料中具有显著分布(χ2检验，p=0.009),而肺炎支原体为6.3%，肺炎衣原体为2.1%，表明COVID-19患者的总合并感染率为21%。无显著性差异(χ2检验，p=0.628）在男性和女性患者之间存在细菌共感染的分布。在5％的共感染患者中确认了降钙素原阳性。
结论：我们的研究记录了COVID-19患者中社区获得性细菌共感染的血清阳性率。在这项研究中,降钙素原是COVID-19患者非严重细菌共感染的不确定性生物标志物。考虑和适当检测社区获得性细菌共感染可以最大程度地减少当前大流行期间的误诊，并积极反映疾病管理和预后。
